SNY Key Statistics, Chart & Performance
The current stock price of SNY is 48.69 USD. In the past month the price increased by 2.16%. In the past year, price decreased by -10.77%.
SNY Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to SNY. When comparing the yearly performance of all stocks, SNY is a bad performer in the overall market: 78.32% of all stocks are doing better.
SNY Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to SNY. SNY scores excellent on profitability, but there are concerns on its financial health.
SNY Financial Highlights
Over the last trailing twelve months SNY reported a non-GAAP Earnings per Share(EPS) of 4.69. The EPS increased by 1.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.63% | ||
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| Debt/Equity | 0.18 |
SNY Forecast & Estimates
29 analysts have analysed SNY and the average price target is 58.84 USD. This implies a price increase of 20.84% is expected in the next year compared to the current price of 48.69.
For the next year, analysts expect an EPS growth of 8.1% and a revenue growth 6.49% for SNY
SNY Ownership
SNY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.46 | 969.015B | ||
| JNJ | JOHNSON & JOHNSON | 20.59 | 574.257B | ||
| MRK | MERCK & CO. INC. | 21.78 | 290.769B | ||
| PFE | PFIZER INC | 9.18 | 156.982B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.92 | 123.896B | ||
| ZTS | ZOETIS INC | 18.8 | 56.466B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.55 | 25.52B | ||
| VTRS | VIATRIS INC | 6.28 | 18.371B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.59 | 12.725B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.53 | 9.291B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SNY
Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Company Info
SANOFI-ADR
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE 75008 FR
CEO: Paul Hudson
Employees: 84587
Phone: 33153774000
SANOFI-ADR / SNY FAQ
What does SNY do?
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Can you provide the latest stock price for SANOFI-ADR?
The current stock price of SNY is 48.69 USD. The price increased by 0.12% in the last trading session.
Does SANOFI-ADR pay dividends?
SANOFI-ADR (SNY) has a dividend yield of 5.08%. The yearly dividend amount is currently 2.25.
How is the ChartMill rating for SANOFI-ADR?
SNY has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about SANOFI-ADR (SNY) stock?
29 analysts have analysed SNY and the average price target is 58.84 USD. This implies a price increase of 20.84% is expected in the next year compared to the current price of 48.69.
Can you provide the sector and industry classification for SANOFI-ADR?
SANOFI-ADR (SNY) operates in the Health Care sector and the Pharmaceuticals industry.
What is the market capitalization of SNY stock?
SANOFI-ADR (SNY) has a market capitalization of 117.60B USD. This makes SNY a Large Cap stock.